U.S. Introduces Tariffs on Patented Pharmaceutical Products to Strengthen Supply Chains

 

Summary 

• New Section 232 tariffs introduce a 100% duty on patented pharmaceutical products and ingredients, with differentiated rates, timelines, and exemptions aimed at strengthening U.S. national security and public health.
• Targeted relief and incentives are offered through trade‑deal country tariffs, onshoring commitments, and Most Favored Nation (MFN) pricing agreements, potentially reducing tariffs to 0% through January 20, 2029.
• Supply chain resilience focus aligns tariffs with broader industrial policy measures, investment commitments, and monitoring mechanisms to rebuild domestic pharmaceutical manufacturing capacity.

Source Whitehouse.gov

---

Article

On April 2, 2026, the United States announced the imposition of tariffs on patented pharmaceutical products and their ingredients under Section 232 of the Trade Expansion Act of 1962, citing risks to national security and public health arising from heavy import dependence. The measures apply primarily to patented medicines and inputs, while leaving generics and biosimilars outside the scope—for now.

At the core of the action is a 100% tariff on patented pharmaceutical products and ingredients. Implementation will be phased: larger companies face entry into force after 120 days, while smaller companies are granted 180 days. A differentiated framework applies to countries with established trade arrangements. Pharmaceuticals originating from the European Union, Japan, Korea, Switzerland, and Liechtenstein are subject to a 15% tariff, while products from the United Kingdom benefit from a lower rate under a recently concluded UK‑U.S. pharmaceutical agreement.

The framework is designed to encourage onshoring and pricing commitments. Companies entering into Most Favored Nation (MFN) pricing agreements with the Department of Health and Human Services (HHS), alongside onshoring agreements with the Department of Commerce, may qualify for a 0% tariff through January 20, 2029. Firms that commit to onshoring alone face a reduced 20% tariff. Federal agencies will provide structured pathways for companies to negotiate and enter these agreements.

Several exemptions and carve‑outs apply. Generic medicines, biosimilars, and their ingredients are excluded at this stage, though the policy will be reassessed after one year. Orphan drugs, animal health products, and certain specialty pharmaceuticals may also be exempt when sourced from trade‑deal countries or when justified by urgent public health needs. To ensure effectiveness, the Proclamation establishes strong monitoring and enforcement measures, including external audits and the possibility of tariff increases on past and future imports in cases of non‑compliance.

The tariffs follow an extensive Department of Commerce investigation concluding that imports of patented pharmaceuticals and related ingredients threaten to impair U.S. national security. While the U.S. remains a global leader in pharmaceutical research and development, reliance on foreign manufacturing was identified as a vulnerability—particularly in the context of global supply chain disruptions. The administration reports that anticipation of the measures has already spurred approximately $400 billion in new U.S. investment commitments by domestic and foreign pharmaceutical companies during the current term.

These steps build on earlier actions to enhance pharmaceutical supply chain resilience, including executive measures adopted in May 2025 to reduce regulatory barriers to domestic drug manufacturing and in August 2025 to establish a strategic reserve of active pharmaceutical ingredients. Parallel Section 232 investigations in adjacent sectors—such as medical equipment, consumables, and robotics—underline a broader strategy to safeguard critical industries.

Collectively, the tariffs and accompanying incentives signal a shift toward industrial policy tools aimed at rebuilding domestic pharmaceutical manufacturing, balancing supply security with pricing considerations, and reducing dependence on foreign sources for essential medicines.

---

---